Melanotan2 10MG
$29.00MG
Melanotan-2 (MT-2) has become one of the most widely discussed compounds in pigmentation research due to its interaction with melanocortin receptors involved in skin pigmentation pathways. Researchers are interested in Melanotan 2 for its potential to influence melanin production and better understand the biological mechanisms that affect pigmentation response. Its long-standing presence in the research community has made it a frequent subject of investigation for studies exploring melanocortin signaling, pigmentation processes, and related physiological pathways. As interest in appearance, UV response, and melanocortin biology continues to grow, Melanotan 2 remains a popular compound among researchers seeking to better understand these complex systems.
29 Athena Points with this purchaseIn stock
Overview
Melanotan 2 represents a revolutionary advancement in melanocortin receptor research. This cyclic heptapeptide analog of α-MSH features a unique lactam bridge structure that enables broad receptor activation across MC1R, MC3R, MC4R, and MC5R. Unlike its linear predecessor Melanotan 1, MT-2’s compact cyclic architecture provides enhanced stability and multi-system biological activity. Originally developed for pigmentation research, MT-2 has emerged as a valuable tool for investigating diverse physiological processes including sexual function, appetite regulation, and energy homeostasis. Its non-selective receptor profile makes it particularly valuable for studying the interconnected nature of melanocortin signaling pathways.
Key Characteristics
MOLECULAR PROFILE
- Formula: C50H69N15O9
- Weight: 1024.20 g/mol
- CAS: 121062-08-6
- Structure: Cyclic heptapeptide with lactam bridge
PHYSICAL PROPERTIES
- Form: White to off-white lyophilized powder
- Solubility: Soluble in water and acetic acid
- Selectivity: Non-selective MC1R/3R/4R/5R agonist
- Storage: Keep refrigerated 36‑46 °F (2‑8 °C)
How It Works
Primary Mechanisms
Multi-Receptor Binding
Activates MC1R, MC3R, MC4R, and MC5R simultaneously
G-Protein Coupling
Triggers Gs-mediated cAMP accumulation across cell types
PKA Activation
Phosphorylates CREB and other transcription factors
Cyclic Structure
Lactam bridge provides enhanced stability and bioavailability
System-Specific Effects
Melanogenesis (MC1R)
Stimulates eumelanin production in melanocytes
Sexual Function (MC4R)
Modulates arousal pathways in the CNS
Energy Balance (MC3R/4R)
Influences appetite and metabolic regulation
Research Findings
Enhanced Melanogenesis
- 10-fold greater potency than natural α-MSH
- Rapid onset of pigmentation without UV exposure
- Sustained melanin production after discontinuation
- Darkening of melanocytic nevi observed
Sexual Response Studies
- Spontaneous erectile responses in male subjects
- Increased arousal in both sexes via CNS pathways
- Led to development of bremelanotide (PT-141)
- Activation of hypothalamic circuits
Metabolic Regulation
- Reduced appetite through MC4R activation
- Altered fat metabolism in animal models
- Influence on insulin sensitivity markers
- Thermogenic effects observed
Behavioral Modulation
- Reduced addictive behaviors in models
- Altered reward pathway signaling
- Potential dopaminergic interactions
- Effects on social behavior patterns
Potential Side Effects in Research
Nausea and Reduced Appetite
Common gastrointestinal effects via MC4R
Stretching and Yawning
Central melanocortin system activation
Facial Flushing
Vasodilation and increased blood flow
Spontaneous Erections
MC4R activation in male subjects
References
- Maurya MR, Munshi R, Zambare S. Melanocortin Receptors: Emerging Targets for the Treatment of Pigmentation, Inflammation, Stress, Weight Disorders and Sexual Dysfunction. Curr Drug Targets. 2023;24(2):151-156.
- Li H, Xu Y, Jiang Y, et al. The melanocortin action is biased toward protection from weight loss in mice. Nat Commun. 2023;14:2200.
- Goit RK, Taylor AW, Lo ACY. The central melanocortin system as a treatment target for obesity and diabetes: A brief overview. Eur J Pharmacol. 2022;924:174956.
- De Jonghe BC, Hayes MR, Bence KK. Melanocortin control of energy balance: evidence from rodent models. Cell Mol Life Sci. 2011;68(15):2569-2588.
- Edinoff AN, Sanders NM, Lewis KB, et al. Bremelanotide for Treatment of Female Hypoactive Sexual Desire. Neurol Int. 2022;14(1):75-88.
- Dorr RT, Lines R, Levine N, et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci. 1996;58(20):1777-1784.
Related products
